What Immune Biosolutions does

Immune Biosolutions is a privately held, clinical-stage biotechnology company headquartered in Sherbrooke, Quebec, that operates an integrated antibody discovery, engineering, and biomanufacturing platform. Its core technology exploits the phylogenetic distance of the avian (chicken) immune system to generate antibodies against highly conserved mammalian targets, complemented by three screening modalities — phage display (10^11-12 library size), yeast display (10^9), and single B-cell screening — and an engineering stack covering humanization, affinity maturation, bispecific/multispecific formats, and ML-based codon optimization. The company serves pharmaceutical and biotechnology companies, academic and commercial research laboratories, and strategic partners requiring custom antibody development and GMP-compliant manufacturing.

The company monetizes across four streams: (1) fee-for-service CDMO biomanufacturing using its GMP and non-GMP facility (ISO 7/ISO 5 clean rooms), (2) custom antibody discovery programs offered as standalone services or integrated pipelines, (3) direct online sales of research-grade recombinant monoclonal antibodies (e.g., Rituximab, Trastuzumab, Adalimumab biosimilars) priced from C$600 to C$15,000, and (4) licensing and partnership revenue from therapeutic programs. Customers are exclusively qualified research institutions and professional users, not consumers.

Internally, Immune Biosolutions is advancing a three-asset pipeline: IBIO123, an inhaled three-antibody cocktail for COVID-19 that completed Phase 1/2 trials and demonstrated 100% in vitro neutralization of SARS-CoV-2 variants of concern including Omicron; IBIO301, an immuno-oncology candidate targeting LILRB1/2 in pre-clinical; and IBIO401, a TCR-mimic pediatric leukemia program partnered with an undisclosed developer and extended via the related Neomabs Biotechnologies entity. Since founding, the company has secured approximately C$15.5 million in cumulative funding (notably a C$13.44M Strategic Innovation Fund grant in 2021 and a C$1.1M CQDM grant in 2018), established a research collaboration with Janssen Biotech, and built a Scientific Advisory Board drawing from Université de Montréal, Darmstadt Technical University, and former Novartis Canada leadership.

Name

Immune Biosolutions

Legal name

Immune Biosolutions Inc.

Website

https://immunebiosolutions.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Immune Biosolutions is a Sherbrooke, Canada-based clinical-stage biotech operating an avian immune system-based antibody discovery, engineering, and GMP biomanufacturing platform serving pharmaceutical, biotechnology, and academic research customers.

Ownership category

akta.pro rank

Product category

Contract Antibody Discovery & Biomanufacturing Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Bispecific & Multispecific Antibodies (HLAAAAAF), Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)

Keywords

• Antibody discovery services
• Contract biomanufacturing
• Therapeutic antibody engineering
• Biopharmaceutical CDMO services
• Recombinant antibody production

Headquarters

HQ city

Sherbrooke

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing (CDMO Services): Fee-for-service biomanufacturing services offered to pharmaceutical and biotechnology partners. Includes protein expression, purification, and analytics for pre-clinical and clinical studies.
2. Antibody Product Sales: Direct sales of recombinant monoclonal antibodies through online shop. Products include research-grade functional antibodies such as Rituximab, Trastuzumab, Adalimumab, and custom antibodies. Prices range from $600 to $15,000 CAD depending on quantity and format.
3. Custom Antibody Discovery Services: Integrated discovery pipeline offered as standalone services or complete programs. Partners can access immunization, screening, engineering, and production services tailored to their specific therapeutic targets.
4. Licensing and Partnership Revenue: Strategic partnerships and licensing agreements for therapeutic antibody programs. The company has established collaborations with Janssen Biotech and is actively seeking partnerships for IBIO123 and other pipeline assets.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels4 records

Core offering

Immune Biosolutions provides custom antibody discovery, engineering, and GMP biomanufacturing services to pharmaceutical, biotechnology, and research customers. Its proprietary platform combines an avian (chicken) immune system with phage display, yeast display, and single B-cell screening technologies, complemented by computational humanization, AI-driven codon optimization, affinity maturation, and bispecific engineering. The company also sells research-grade recombinant monoclonal antibodies and custom IgY polyclonal antibodies through an online shop, and develops an internal therapeutic pipeline including IBIO123 (COVID-19, completed Phase 1/2), IBIO301 (immuno-oncology), and IBIO401 (pediatric leukemia).

Product overview

Immune Biosolutions is a clinical-stage biotechnology company offering an integrated platform for antibody discovery, engineering, and biomanufacturing. The company's service portfolio includes Antibody Discovery (using phage display, yeast display, and single B-cell technologies), Antibody Engineering (bispecific/multispecific antibodies, humanization, affinity maturation, codon optimization), Antibody Characterization (SPR and BLI analysis), and Biomanufacturing (GMP/non-GMP production). Their online shop sells research-grade recombinant monoclonal antibodies including Trastuzumab, Rituximab, Infliximab, Bevacizumab, Adalimumab, and SARS-CoV-2 mAb CV3-25. The company also maintains an internal pipeline with drug candidates IBIO301 (immuno-oncology) and IBIO401 (pediatric leukemia). Their differentiated approach leverages the avian immune system to generate novel antibodies with increased reactivity and greater paratope diversity.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Discovery Platform Integrated antibody discovery service for custom programs covering immunization (avian and human), screening (phage display, yeast display, single B cell), engineering, production, and validation for therapeutic and diagnostic applications. Targeted at pharmaceutical, biotechnology, and research institution partners.
• Antibody Selection Services Standalone antibody selection services spanning three complementary methods: phage display (10^11-10^12 library size, prokaryotic expression, scFv/VHH/Fab formats), yeast display (10^9 library size, natively paired VH/VL), and single B-cell screening via fluorescent microscopy with natively paired heavy/light chains. For partners requiring specific selection method capabilities.
• Antibody and Protein Production Protein expression and purification service using CHO and HEK cells for stable pools and transient expression, supporting formats including IgG1, IgG4, IgG2a, IgA, scFv, Nano-TCR, and Fc-fusion proteins. For partners needing research- and pre-clinical-grade recombinant protein production.
• Bispecific and Multispecific Antibody Engineering Engineering service for bispecific and trispecific antibodies using knob-into-hole, CrossMAb, and IgG-scFv platforms, supported by computational modeling and structure-guided design. For partners developing multifunctional antibody therapeutics.
• Antibody Humanization CDR grafting and structure-guided engineering service to transfer antigen-binding regions from animal-derived antibodies onto optimized human frameworks, offered in standard humanization, hyper-humanization, and high-resolution hyper-humanization pipelines. For partners needing to reduce immunogenicity of non-human antibody leads.
• Affinity Maturation Three-tiered antibody optimization service to increase affinity and specificity, ranging from CDRH3 substitution matrix through VH/VL static modeling optimization to molecular dynamics-driven high-resolution affinity maturation. For partners needing to improve lead antibody binding properties.
• Codon Optimization AI/ML-powered codon optimization service using a machine-learning-based algorithm to optimize DNA sequences for protein and antibody expression in any host organism including CHO and HEK cells. For partners requiring enhanced protein expression yields.
• Antibody Characterization Antibody screening and binding analysis service using Carterra LSA (high-throughput SPR, up to 1,152 clones per run) and Octet RED384 (BLI, up to 384 clones per run) for binding kinetics, affinity measurement, epitope binning, and mapping. For partners needing detailed biophysical characterization.
• Biomanufacturing Services (CDMO) Contract Development and Manufacturing Organization (CDMO) service for antibody and recombinant protein production under GMP and non-GMP standards, with ISO 7 and ISO 5 clean rooms and full upstream and downstream processing. For pharmaceutical and biotechnology partners needing pre-clinical and clinical material supply.
• Polyclonal IgY Antibodies Custom polyclonal antibody production service using chicken egg yolks (IgY format), offering high yields, 10-year stability at 4°C, and non-invasive production. For research and diagnostic partners requiring polyclonal reagents.
• Trastuzumab (Anti-HER2) Recombinant Antibody – Functional Grade Humanized monoclonal IgG1 antibody targeting the HER2 (ERBB2) receptor, available in 0.1, 1, 5, 10, and 25 mg sizes for research use by qualified research institutions, laboratories, and professional users.
• Rituximab (Anti-CD20) Recombinant Antibody – Functional Grade Chimeric monoclonal IgG1 antibody targeting CD20 (MS4A1) antigen on B cells, available for research use in immunology and B cell research applications by qualified research institutions and professional users.
• Infliximab (Anti-TNF-α) Recombinant Antibody – Functional Grade Chimeric monoclonal IgG1 antibody targeting TNF-α (tumor necrosis factor alpha), a pro-inflammatory cytokine, available for research use by qualified institutions.
• Bevacizumab (Anti-VEGF-A) Recombinant Antibody – Functional Grade Humanized monoclonal IgG1 antibody targeting VEGF-A (vascular endothelial growth factor A), a key driver of angiogenesis, available for research use by qualified institutions.
• Adalimumab (Anti-TNF-α) Recombinant Antibody – Functional Grade Fully human monoclonal IgG1 antibody targeting TNF-α, a key mediator of inflammatory processes, available for research use by qualified institutions.
• SARS-CoV-2 mAb (CV3-25) Monoclonal antibody that binds to the S2 protein of all known SARS-CoV-2 strains, sold for SARS-CoV-2 neutralization research applications by qualified institutions.

Quantifiable outcome

• IBIO123 demonstrated 100% neutralization of all SARS-CoV-2 variants of concern including Omicron in vitro
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature11 records

Partnerships

Four partnerships are on record, tiered supporting and core.

• Neomabs BiotechnologiessupportingStrategic or Co-development Partner · 7 June 2023Related company launched in Montreal focused on developing new immunotherapies for pediatric leukemia treatment. Immune Biosolutions' technology contributes to Neomabs' programs.
• DIEX Recherche, Université de Sherbrooke, Keyrus Life SciencesupportingStrategic or Co-development Partner · 20 April 2020Partnership to fight COVID-19 combining expertise in clinical research, academic research, and data analytics.
• Janssen Biotech (Johnson & Johnson)coreStrategic or Co-development Partner · 6 August 2018Research collaboration and license agreement to identify and develop therapeutic antibodies. Part of Johnson & Johnson Innovation network.
• 9Bio TherapeuticscoreStrategic or Co-development PartnerCollaboration on antibody optimization including affinity maturation, humanization, and bispecific antibody engineering. 9Bio provides computational design and structure-guided engineering capabilities complementing Immune Biosolutions' discovery platform.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Creative Biolabs: Custom antibody discovery and engineering services company offering phage display, hybridoma, humanization, and bispecific antibody services. Closely comparable boutique CRO with overlapping service lines and customer base.
• AbCellera Biologics: Vancouver-based antibody discovery platform company using single B-cell screening and display technologies, with internal therapeutic programs. Direct competitor in the boutique antibody discovery space and a useful size/scale benchmark for Immune Biosolutions' ambitions.
• GenScript ProBio: Integrated CDMO and discovery services provider offering antibody development, engineering, and GMP manufacturing — directly overlapping Immune Biosolutions' discovery-to-manufacturing value chain on a much larger global scale.
• Sino Biological: Major recombinant antibody and reagent manufacturer with a catalog of research-grade antibodies (including biosimilar-grade products like Trastuzumab, Rituximab). Direct competitor to Immune Biosolutions' online catalog and custom services.
• Adimab: Leading yeast-display-based antibody discovery platform offering fully integrated engineering and optimization services to pharma partners. Closely comparable to Immune Biosolutions' yeast display, humanization, and affinity maturation offerings.

Broad incumbents

• Bio-Rad Laboratories: Established life sciences tools company supplying research antibodies, protein characterization instruments (SPR, BLI), and reagents. Comparable in the catalog reagent and antibody characterization segments, with greater scale and brand recognition.
• Catalent: Large global CDMO with biologics manufacturing capabilities across multiple modalities. Competes for the same CDMO and biomanufacturing engagements that Immune Biosolutions targets, though at a fundamentally larger scale.
• Charles River Laboratories: Global CRO/CDMO with significant biologics and antibody discovery services, including the acquired Distributed Bio antibody discovery platform. Comparable as an integrated drug discovery and manufacturing services competitor.
• WuXi Biologics: Global leader in biologics CDMO services with massive GMP capacity. Competes with Immune Biosolutions' CDMO and biomanufacturing services at the high end of the market, particularly for clinical and commercial-stage programs.

Emerging players

• Distributed Bio (Charles River): Antibody discovery and engineering platform originally independent, now part of Charles River Laboratories. Comparable in offering custom antibody libraries and engineering services, though now operating within a much larger parent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/iBiosolutions

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immune Biosolutions